Replies to post #30463 on Anavex Life Sciences Corp (AVXL)

[Millstone]

Interesting - In the abstract you have linked to that is combined with all the others, there is more 'color' to the data:

In the secondary outcome endpoints preliminary
analysis of data from subjects to date shows an average improvement
of the MMSE score at week 12 in PART B (week 17 from baseline).
A significant majority of all patients tested so far improved their
respective MMSE score. The average EEG/ERP (P300 amplitude)
signal also improved and also the average Cogstate test improved
across the test batteries.
Conclusions:
Data collected so far indicate
that ANAVEX 2-73 is safe and well tolerated. Interim results also
show improved cognitive performance after drug administration in
subjects with mild-to-moderate AD.